Lund, SE — August 26, 2025 — Leads & Copy — BioInvent International (STO:BINV) is sharpening its clinical focus on its most advanced assets to enhance patient impact and shareholder value, according to CEO Martin Welschof. This strategic move follows the presentation of promising Phase 2a monotherapy data for BI-1808 in CTCL at EHA 2025, positive Phase 1 data for BI-1206 with KEYTRUDA® in solid tumors, and a poster presentation on BI-1910 at PAGE 2025.
Other Q2 events include XOMA Royalty’s purchase of mezagitamab rights for up to USD 30 million, updated Phase 2a data of BI-1206 with rituximab and Calquence in non-Hodgkin’s lymphoma, and FDA Fast Track Designation for BI-1808 in cutaneous T-cell lymphoma. Takeda also moved mezagitamab into Phase 3, triggering a milestone payment to BioInvent.
Post-period events include strategic portfolio changes and an upcoming presentation of BT-001 data at ESMO 2025 with Transgene.
Second quarter financial highlights include net sales of SEK 198.1 million, profit after tax of SEK 38.8 million, and liquid funds of SEK 797.5 million.
Cecilia Hofvander, VP Investor Relations can be reached at +46 (0)46 286 85 50 or cecilia.hofvander@bioinvent.com.
Source: BioInvent International
